JPS61176523A - 制癌剤 - Google Patents
制癌剤Info
- Publication number
- JPS61176523A JPS61176523A JP60016085A JP1608585A JPS61176523A JP S61176523 A JPS61176523 A JP S61176523A JP 60016085 A JP60016085 A JP 60016085A JP 1608585 A JP1608585 A JP 1608585A JP S61176523 A JPS61176523 A JP S61176523A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- differentiation
- compound
- strong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003327 cancerostatic effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 32
- 201000011510 cancer Diseases 0.000 abstract description 30
- 230000004069 differentiation Effects 0.000 abstract description 18
- 208000032839 leukemia Diseases 0.000 abstract description 14
- 230000001939 inductive effect Effects 0.000 abstract description 13
- 231100000419 toxicity Toxicity 0.000 abstract description 10
- 230000001988 toxicity Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 241000700605 Viruses Species 0.000 abstract description 4
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 abstract description 4
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- YECWTLGLNDDPGE-PIFXLSLCSA-N trichostatin C Chemical compound C(/[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)=C(/C)\C=C\C(=O)NO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YECWTLGLNDDPGE-PIFXLSLCSA-N 0.000 abstract description 3
- YECWTLGLNDDPGE-UHFFFAOYSA-N trichostatin D Natural products C=1C=C(N(C)C)C=CC=1C(=O)C(C)C=C(C)C=CC(=O)NOC1OC(CO)C(O)C(O)C1O YECWTLGLNDDPGE-UHFFFAOYSA-N 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001857 anti-mycotic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 47
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 241000714180 Rauscher mink cell focus-forming virus Species 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- -1 alkali metal salts Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000000468 rubriblast Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 1
- 244000039154 Erica Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009095 third-line therapy Methods 0.000 description 1
- 229930185603 trichostatin Natural products 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60016085A JPS61176523A (ja) | 1985-01-30 | 1985-01-30 | 制癌剤 |
| US06/821,973 US4690918A (en) | 1985-01-30 | 1986-01-24 | Use of trichostatin compounds for treating tumor cells |
| DE8686101047T DE3682091D1 (de) | 1985-01-30 | 1986-01-27 | Trichostatine a und c als antikrebsmittel. |
| EP86101047A EP0196415B1 (en) | 1985-01-30 | 1986-01-27 | Trichostatins a and c as antitumour drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60016085A JPS61176523A (ja) | 1985-01-30 | 1985-01-30 | 制癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61176523A true JPS61176523A (ja) | 1986-08-08 |
| JPH0466453B2 JPH0466453B2 (OSRAM) | 1992-10-23 |
Family
ID=11906699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60016085A Granted JPS61176523A (ja) | 1985-01-30 | 1985-01-30 | 制癌剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4690918A (OSRAM) |
| EP (1) | EP0196415B1 (OSRAM) |
| JP (1) | JPS61176523A (OSRAM) |
| DE (1) | DE3682091D1 (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
| JP2007262058A (ja) * | 2006-03-03 | 2007-10-11 | Tokyo Univ Of Science | 糸状菌の分化抑制剤 |
| JP2016528297A (ja) * | 2013-08-22 | 2016-09-15 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 癌治療 |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0775593A (ja) * | 1993-09-08 | 1995-03-20 | Suntory Ltd | 蛋白質の製造方法 |
| EP0827946A1 (en) * | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Inhibitors for the differentiation of cells, in particular hepatic stellate cells |
| AU5722398A (en) * | 1996-12-30 | 1998-07-31 | Johns Hopkins University School Of Medicine, The | Compositions and methods for restoring a normal pattern of imprinting to cells |
| EP1332756A3 (en) * | 1996-12-30 | 2003-12-10 | The Johns Hopkins University School Of Medicine | Compositions and methods for restoring a normal pattern of imprinting to cells |
| US6387673B1 (en) * | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
| AUPO721997A0 (en) * | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| US6518012B1 (en) | 1999-04-02 | 2003-02-11 | Health Research, Inc. | Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation |
| US6544957B2 (en) | 2000-01-04 | 2003-04-08 | The Johns Hopkins University | Methods and reagents for facilitating transcription |
| WO2002055017A2 (en) * | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| AR035659A1 (es) * | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| DE60113645T2 (de) * | 2001-04-10 | 2006-07-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2002102981A2 (en) * | 2001-06-15 | 2002-12-27 | The Trustees Of Columbia University In The City Of New York | SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS |
| JP4638148B2 (ja) * | 2001-10-16 | 2011-02-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 神経変性疾患および脳の癌の処置 |
| US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| AU2003219803B8 (en) * | 2002-02-15 | 2005-08-25 | Sloan-Kettering Institute For Cancer Research | Method of treating TRX mediated diseases |
| EP1485076A1 (en) * | 2002-02-27 | 2004-12-15 | The Ohio State University Research Foundation | Therapeutic methods for acute myeloid leukemia |
| US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| EP2266552A3 (en) * | 2002-03-04 | 2011-03-02 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| CN100566711C (zh) * | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| US20040162263A1 (en) * | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
| DK2238982T3 (da) | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| CA2535806C (en) * | 2003-08-26 | 2009-02-17 | Aton Pharma, Inc. | The use of hdac inhibitors for the treatment of cancer |
| US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| US7875275B2 (en) * | 2004-06-16 | 2011-01-25 | The General Hospital Corporation | Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes |
| US20060063735A1 (en) * | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| AU2006283677A1 (en) * | 2005-08-19 | 2007-03-01 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Topical formulations of histone deacetylase inhibitors and methods of using the same |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070105792A1 (en) * | 2005-11-04 | 2007-05-10 | Dimartino Jorge F | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
| US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
| CN101300015A (zh) * | 2005-11-04 | 2008-11-05 | 默克公司 | 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法 |
| US20070197473A1 (en) * | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
| US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
| CA2664985A1 (en) * | 2006-09-29 | 2008-04-10 | The Board Of Trustees Of The University Of Illinois | Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism |
| CN101528037A (zh) * | 2006-11-03 | 2009-09-09 | 默克公司 | 使用saha和硼替佐米治疗多发性骨髓瘤的方法 |
| MX2009008347A (es) | 2007-02-06 | 2009-10-19 | Lixte Biotechnology Holdings I | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. |
| US8043804B2 (en) * | 2007-05-23 | 2011-10-25 | The Trustees Of Columbia University In The City Of New York | DBC1, a novel native inhibitor of anti-aging protein SIRT1 |
| EP2185173A4 (en) * | 2007-08-03 | 2011-01-12 | Lixte Biotechnology Inc | USE OF PHOSPHATASES FOR THE TREATMENT OF NEUROBLASTOMES AND MEDULLOGASTOMES |
| MX2010003417A (es) * | 2007-10-01 | 2010-09-10 | Lixte Biotechnology Inc | Inhibidores de histona desacetilasa. |
| AU2009277086B2 (en) * | 2008-08-01 | 2015-12-10 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| EP2309853A4 (en) * | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE |
| US8227473B2 (en) * | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| EP2750768B1 (en) | 2011-08-30 | 2018-10-03 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| BR112015025852A2 (pt) | 2013-04-09 | 2017-07-25 | Lixte Biotechnology Inc | as formulações de oxabicicloheptanos e oxabicicloheptenos |
| WO2015027125A1 (en) * | 2013-08-22 | 2015-02-26 | Vanda Pharmaceuticals Inc. | Multiple myeloma treatment |
| EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| MX2018000016A (es) | 2015-07-02 | 2019-01-31 | Otsuka Pharma Co Ltd | Composiciones farmaceuticas liofilizadas. |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US12168008B2 (en) | 2016-12-08 | 2024-12-17 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
| CA3071755A1 (en) | 2017-08-03 | 2019-02-07 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60149520A (ja) * | 1984-01-13 | 1985-08-07 | Ajinomoto Co Inc | 抗腫瘍剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4218478A (en) * | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
-
1985
- 1985-01-30 JP JP60016085A patent/JPS61176523A/ja active Granted
-
1986
- 1986-01-24 US US06/821,973 patent/US4690918A/en not_active Expired - Fee Related
- 1986-01-27 DE DE8686101047T patent/DE3682091D1/de not_active Expired - Lifetime
- 1986-01-27 EP EP86101047A patent/EP0196415B1/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60149520A (ja) * | 1984-01-13 | 1985-08-07 | Ajinomoto Co Inc | 抗腫瘍剤 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
| JP2007262058A (ja) * | 2006-03-03 | 2007-10-11 | Tokyo Univ Of Science | 糸状菌の分化抑制剤 |
| JP2016528297A (ja) * | 2013-08-22 | 2016-09-15 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 癌治療 |
| US10265282B2 (en) | 2013-08-22 | 2019-04-23 | Vanda Pharmaceuticals Inc. | Cancer treatment |
| JP2019167351A (ja) * | 2013-08-22 | 2019-10-03 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 癌治療 |
| JP2021105005A (ja) * | 2013-08-22 | 2021-07-26 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 癌治療 |
| US11078289B2 (en) | 2013-08-22 | 2021-08-03 | Vanda Pharmaceuticals Inc. | Cancer treatment |
| US11667718B2 (en) | 2013-08-22 | 2023-06-06 | Vanda Pharmaceuticals Inc. | Cancer treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0466453B2 (OSRAM) | 1992-10-23 |
| EP0196415B1 (en) | 1991-10-23 |
| US4690918A (en) | 1987-09-01 |
| DE3682091D1 (de) | 1991-11-28 |
| EP0196415A2 (en) | 1986-10-08 |
| EP0196415A3 (en) | 1988-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61176523A (ja) | 制癌剤 | |
| Bentley | Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant | |
| US5244922A (en) | Methods for treating viral infections | |
| EP0552373B1 (en) | Apoptosis regulator | |
| ES2312884T3 (es) | Composiciones antivirales que comprenden derivados de acido fenilacetico. | |
| EP1369119B1 (en) | Il-12 expression controlling agents | |
| KR20190009790A (ko) | Apds의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체 | |
| Jiang et al. | Tumor Microenvironment Reprogrammed Bimetallic Hybrid Nanostimulator for Triggering Radio‐Cuproptosis‐Immunotherapy | |
| WO2021180093A1 (zh) | 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途 | |
| Li et al. | Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response | |
| Poydock et al. | Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumors | |
| Zhang et al. | Favipiravir ameliorates bleomycin-induced pulmonary fibrosis by reprogramming M1/M2 macrophage polarization | |
| US20240382484A1 (en) | Composition for treating, preventing, or ameliorating melanoma and method thereof | |
| US20200230115A1 (en) | Methods of treating influenza-associated viral pneumonia | |
| CN115227687A (zh) | 浅蓝菌素在制备防治nlrp3炎症小体相关疾病的药物中的应用 | |
| US5089508A (en) | Methods for treating aids | |
| JP5145563B2 (ja) | 神経変性疾患治療薬 | |
| Sodhi et al. | Production of reactive nitrogen intermediates by bone marrow‐derived macrophages on treatment with cisplatin in vitro | |
| CA2300792A1 (en) | An agent for increasing chemokine production | |
| RU2814013C1 (ru) | Способ использования 4-((5,10-диметил-6-оксо-6,10-дигидро-5Н-пиримидо[5,4-b]тиено[3,2-e][1,4]диазепин-2-ил)амино)бензолсульфонамида (XMU-MP-1) для подавления роста клеток лимфомы Беркитта | |
| EP0476391A2 (en) | Anti-AIDS virus composition containing cepharanthine as active compound | |
| Dore-Duffy et al. | Oral administration of prostaglandin E2 to humans: Effects on peripheral blood leukocyte function | |
| RU2784809C2 (ru) | Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения | |
| US5658912A (en) | Apoptosis regulating composition | |
| CN117159540A (zh) | Benzosceptrin C的医药用途 |